Company
Every investor coverage indicates participated in a round Cure Kids Ventures raised.
Companies Cure Kids Ventures acquired or merged with, per published coverage. Buying a company is not investing in one: nothing here counts in the deals column.
Stories naming Cure Kids Ventures. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Roundup of eight Australian and New Zealand startups whose late-July funding totals $102 million across space capsules, medical devices, livestock breath analysis, sports analytics and AI crop forecasting.
Weekly roundup of ten Australian and New Zealand startup raises totalling nearly $194 million, topped by Neara's $90 million round at a $1.1 billion valuation, with Splose, Operata, HAMR Energy and Adora also covered.
Medtech firm Kitea Health has wrapped an oversubscribed $13 million round, with Icehouse Ventures leading, to fund planned American human trials of its implanted pressure sensor.
Cancer biotech Amaroq Therapeutics appointed four experts to its advisory board as it moves toward clinical trials; the New Zealand company's backers include Brandon Capital, which reports $14m invested to date.
New Zealand biotech Amaroq Therapeutics reported early progress toward clinical trials and appointed four leading scientists to its scientific advisory board, strengthening its lncRNA cancer therapy programme.
Case study on how CSIRO's bioinformatics teams independently validated the cancer-target findings of Amaroq Therapeutics, a New Zealand biotech whose $14m seed round was funded by the Brandon Capital-managed MRCF and others.
New Zealand cancer biotech Amaroq Therapeutics had its lncRNA drug targets independently validated by CSIRO, according to this profile, which also recalls its $14 million seed round and support from Callaghan Innovation.